Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown

Trial Profile

Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Vinorelbine (Primary) ; Erlotinib; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CONFERMER
  • Most Recent Events

    • 29 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top